Table of Content

1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size
1.3 Market Segmentation
1.4 Global Macroeconomic Analysis
1.5 SWOT Analysis

2. Market Dynamics
2.1 Market Drivers
2.2 Market Constraints and Challenges
2.3 Emerging Market Trends
2.4 Impact of COVID-19
2.4.1 Short-term Impact
2.4.2 Long-term Impact

3 Associated Industry Assessment
3.1 Supply Chain Analysis
3.2 Industry Active Participants
3.2.1 Suppliers of Raw Materials
3.2.2 Key Distributors/Retailers
3.3 Alternative Analysis
3.4 The Impact of Covid-19 From the Perspective of Industry Chain

4 Market Competitive Landscape
4.1 Industry Leading Players
4.2 Industry News
4.2.1 Key Product Launch News
4.2.2 M&A and Expansion Plans

5 Analysis of Leading Companies
5.1 Aires Pharmaceuticals
5.1.1 Aires Pharmaceuticals Company Profile
5.1.2 Aires Pharmaceuticals Business Overview
5.1.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.1.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.2 Radikal Therapeutics
5.2.1 Radikal Therapeutics Company Profile
5.2.2 Radikal Therapeutics Business Overview
5.2.3 Radikal Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.2.4 Radikal Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.3 Dong- A ST
5.3.1 Dong- A ST Company Profile
5.3.2 Dong- A ST Business Overview
5.3.3 Dong- A ST Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.3.4 Dong- A ST Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.4 Asklepion Pharmaceuticals
5.4.1 Asklepion Pharmaceuticals Company Profile
5.4.2 Asklepion Pharmaceuticals Business Overview
5.4.3 Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.4.4 Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.5 GlaxoSmithKline
5.5.1 GlaxoSmithKline Company Profile
5.5.2 GlaxoSmithKline Business Overview
5.5.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.5.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.6 Berlin Cures
5.6.1 Berlin Cures Company Profile
5.6.2 Berlin Cures Business Overview
5.6.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.6.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.7 Northern Therapeutics
5.7.1 Northern Therapeutics Company Profile
5.7.2 Northern Therapeutics Business Overview
5.7.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.7.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.8 Novartis
5.8.1 Novartis Company Profile
5.8.2 Novartis Business Overview
5.8.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.8.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.9 AstraZeneca
5.9.1 AstraZeneca Company Profile
5.9.2 AstraZeneca Business Overview
5.9.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.9.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.10 Pfizer
5.10.1 Pfizer Company Profile
5.10.2 Pfizer Business Overview
5.10.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.10.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.11 DEKA Research and Development
5.11.1 DEKA Research and Development Company Profile
5.11.2 DEKA Research and Development Business Overview
5.11.3 DEKA Research and Development Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.11.4 DEKA Research and Development Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.12 United Therapeutics
5.12.1 United Therapeutics Company Profile
5.12.2 United Therapeutics Business Overview
5.12.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.12.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.13 Lung Biotechnology
5.13.1 Lung Biotechnology Company Profile
5.13.2 Lung Biotechnology Business Overview
5.13.3 Lung Biotechnology Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.13.4 Lung Biotechnology Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.14 Eiger BioPharmaceuticals
5.14.1 Eiger BioPharmaceuticals Company Profile
5.14.2 Eiger BioPharmaceuticals Business Overview
5.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.15 SteadyMed Therapeutics
5.15.1 SteadyMed Therapeutics Company Profile
5.15.2 SteadyMed Therapeutics Business Overview
5.15.3 SteadyMed Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.15.4 SteadyMed Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.16 Gilead Sciences
5.16.1 Gilead Sciences Company Profile
5.16.2 Gilead Sciences Business Overview
5.16.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.16.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.17 Merck
5.17.1 Merck Company Profile
5.17.2 Merck Business Overview
5.17.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.17.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.18 DAIICHI SANKYO
5.18.1 DAIICHI SANKYO Company Profile
5.18.2 DAIICHI SANKYO Business Overview
5.18.3 DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.18.4 DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.19 Arena Pharmaceuticals
5.19.1 Arena Pharmaceuticals Company Profile
5.19.2 Arena Pharmaceuticals Business Overview
5.19.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.19.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.20 Actelion Pharmaceuticals
5.20.1 Actelion Pharmaceuticals Company Profile
5.20.2 Actelion Pharmaceuticals Business Overview
5.20.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.20.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.21 AADi
5.21.1 AADi Company Profile
5.21.2 AADi Business Overview
5.21.3 AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.21.4 AADi Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.22 BIAL
5.22.1 BIAL Company Profile
5.22.2 BIAL Business Overview
5.22.3 BIAL Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.22.4 BIAL Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.23 Bayer Healthcare
5.23.1 Bayer Healthcare Company Profile
5.23.2 Bayer Healthcare Business Overview
5.23.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.23.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.24 Reata Pharmaceuticals
5.24.1 Reata Pharmaceuticals Company Profile
5.24.2 Reata Pharmaceuticals Business Overview
5.24.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.24.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.25 PhaseBio Pharmaceuticals
5.25.1 PhaseBio Pharmaceuticals Company Profile
5.25.2 PhaseBio Pharmaceuticals Business Overview
5.25.3 PhaseBio Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.25.4 PhaseBio Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction
5.26 Actelion Pharmaceuticals
5.26.1 Actelion Pharmaceuticals Company Profile
5.26.2 Actelion Pharmaceuticals Business Overview
5.26.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)
5.26.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Introduction

6 Market Analysis and Forecast, By Product Types
6.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Types (2015-2020)
6.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Types (2015-2020)
6.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Types (2015-2020)
6.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Types (2015-2020)
6.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Types (2020-2025)
6.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast Sales and Market Share by Types (2020-2025)
6.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast Revenue and Market Share by Types (2020-2025)
6.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price and Growth Rate by Types (2015-2020)
6.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price and Growth Rate of Inhalation
6.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price and Growth Rate of Injectables
6.3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price and Growth Rate of Oral administration
6.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue and Sales Forecast, by Types (2020-2025)
6.4.1 Inhalation Market Revenue and Sales Forecast (2020-2025)
6.4.2 Injectables Market Revenue and Sales Forecast (2020-2025)
6.4.3 Oral administration Market Revenue and Sales Forecast (2020-2025)

7 Market Analysis and Forecast, By Applications
7.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Applications (2015-2020)
7.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Applications (2015-2020)
7.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Applications (2015-2020)
7.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Applications (2020-2025)
7.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast Sales and Market Share by Applications (2020-2025)
7.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast Revenue and Market Share by Applications (2020-2025)
7.3 Global Revenue, Sales and Growth Rate by Applications (2015-2020)
7.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Sales and Growth Rate of Hospitals (2015-2020)
7.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Sales and Growth Rate of Clinics (2015-2020)
7.3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Sales and Growth Rate of Others (2015-2020)
7.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue and Sales Forecast, by Applications (2020-2025)
7.4.1 Hospitals Market Revenue and Sales Forecast (2020-2025)
7.4.2 Clinics Market Revenue and Sales Forecast (2020-2025)
7.4.3 Others Market Revenue and Sales Forecast (2020-2025)

8 Market Analysis and Forecast, By Regions
8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Regions (2015-2020)
8.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue by Regions (2015-2020)
8.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Regions (2020-2025)

9 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
9.1 Market Overview and Prospect Analysis
9.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Sales and Growth Rate (2015-2020)
9.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue and Growth Rate (2015-2020)
9.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast
9.5 The Influence of COVID-19 on North America Market
9.6 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis by Country
9.6.1 U.S. Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
9.6.2 Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
9.6.3 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate

10 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
10.1 Market Overview and Prospect Analysis
10.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Sales and Growth Rate (2015-2020)
10.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue and Growth Rate (2015-2020)
10.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast
10.5 The Influence of COVID-19 on Europe Market
10.6 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis by Country
10.6.1 Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
10.6.2 United Kingdom Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
10.6.3 France Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
10.6.4 Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
10.6.5 Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
10.6.6 Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate

11 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
11.1 Market Overview and Prospect Analysis
11.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Sales and Growth Rate (2015-2020)
11.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue and Growth Rate (2015-2020)
11.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast
11.5 The Influence of COVID-19 on Asia Pacific Market
11.6 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis by Country
11.6.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
11.6.2 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
11.6.3 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
11.6.4 Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
11.6.5 India Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate

12 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
12.1 Market Overview and Prospect Analysis
12.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Sales and Growth Rate (2015-2020)
12.3 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue and Growth Rate (2015-2020)
12.4 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast
12.5 The Influence of COVID-19 on South America Market
12.6 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis by Country
12.6.1 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
12.6.2 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
12.6.3 Columbia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate

13 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
13.1 Market Overview and Prospect Analysis
13.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Sales and Growth Rate (2015-2020)
13.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue and Growth Rate (2015-2020)
13.4 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast
13.5 The Influence of COVID-19 on Middle East and Africa Market
13.6 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis by Country
13.6.1 UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
13.6.2 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate
13.6.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate

14 Conclusions and Recommendations
14.1 Key Market Findings and Prospects
14.2 Advice for Investors

15 Appendix
15.1 Methodology
15.2 Research Data Source